Neuroimaging of cerebral glucose metabolism and blood fl ow is ideally suited to assay widely-distributed brain circuits as a result of local molecular events and behavioral modulation in the central nervous system. With the progress in novel analytical methodology, this endeavor has succeeded in unraveling the mechanisms underlying a wide spectrum of neurodegenerative diseases. In particular, statistical brain mapping studies have made signifi cant strides in describing the pathophysiology of Parkinson's disease (PD) and related disorders by providing signature biomarkers to determine the systemic abnormalities in brain function and evaluate disease progression, therapeutic responses, and clinical correlates in patients. In this article, we review the relevant clinical applications in patients in relation to healthy volunteers with a focus on the generation of unique spatial covariance patterns associated with the motor and cognitive symptoms underlying PD. These characteristic biomarkers can be potentially used not only to improve patient recruitment but also to predict outcomes in clinical trials.
Introduction
(see reviews [1, 2] ). Postsynaptic dopamine receptor systems can be assayed with radioligands that bind specifically to D 1 or D 2 receptors. In addition, PET has been used to study regional neuronal activity by quantifying restingstate regional cerebral glucose metabolism (rCMRglc)
with [ 18 F]fl uorodeoxyglucose (FDG) [3] and regional cerebral blood flow (rCBF) activation responses with [ 15 O]H 2 O [4] .
Abnormal rCBF distributions in the resting state can also be measured using PET and SPECT perfusion tracers.
In particular, imaging of cerebral metabolism and blood flow has contributed greatly to the understanding of the abnormal brain circuitry underlying the pathophysiology of PD.
PET/SPECT can be particularly useful in assessing the consequences of nigrostriatal dopamine deficiency on the functional networks of the basal ganglia. Although the primary pathological abnormality in PD is located in the substantia nigra, the degeneration of dopaminergic projection neurons to the striatum leads to widespread changes in the functional activity of the basal ganglia [5] .
Specifi cally, the loss of inhibitory dopaminergic input to the striatum increases the inhibitory output from the putamen to the external globus pallidus (GPe), decreases the inhibitory and causes functional over-activity of the STN and internal globus pallidus (GPi), resulting in reduced output from the ventrolateral thalamus to the cortex. This classic model has been modifi ed to emphasize the cognitive dysfunction associated with PD [6] and is linked to concurrent changes in regional glucose metabolism and blood fl ow.
We review the advances in functional brain imaging studies of PD in the resting state based on analyses of rCMRglc and rCBF in patients and healthy volunteers. As in most neurodegenerative conditions, these two variables are considered to be coupled in PD and related to synaptic activity at the regional level. We also summarize the use 
Functional Brain Imaging: Univariate Analyses
PET/SPECT imaging of rCMRglc and rCBF has been used extensively to identify changes in regional brain function in patients with PD comparable to those revealed in experimental animal models [7, 8] . The bulk of this effort is based on the use of SPM to localize regionally specifi c differences and functional-clinical correlates in PD patients scanned when they are off dopaminergic medications.
Functional brain images are spatially transformed into a standard anatomical space to allow mapping analysis on a voxel basis. To reduce inter-individual variability in anatomical and functional substrates, images are usually ratio-normalized to a global mean or other reference value that is assumed to be preserved in the diseased brain.
Consequently, only relative measures of functional brain activity are used in most studies.
Cerebral Metabolism Studies
Because the local rate of glucose metabolism is a direct marker of synaptic activity, PET with FDG has been the most common approach to studying abnormal brain function in PD. By using FDG PET images from multiple cohorts of patients and healthy controls we and other researchers have reported a reproducible pattern of abnormal regional metabolism in PD (Fig. 1 ) characterized bilaterally by increases in the putamen, thalamus, cerebellum, pons, and sensorimotor cortex (SMC), and decreases in the lateral frontal and parieto-occipital areas [9] [10] [11] . This is in accordance with a dual-tracer PET study with both FDG and
showing bilaterally increased energy metabolism in the putamen and pallidum in early unmedicated PD patients [12] .
Regional metabolism in the cerebellum is also elevated in early-stage and advanced PD patients [13, 14] , suggesting that cerebellar hypermetabolic activity in PD is closely linked to akinesia and rigidity but not to tremor. It has been further reported that clinical scores of motor symptoms are correlated positively with rCMRglc in the bilateral putamen and pallidum [15] , and in the midbrain, cerebellum, and motor cortex [16] . These reports indicate a pathophysiologic association between subcortical hypermetabolism and motor dysfunction in PD.
Unique features of cortical hypometabolism in PD have also been frequently reported. An early study reported pronounced occipital hypometabolism in the more severely affected hemisphere in PD [17] . The asymmetry in this metabolic reduction correlated inversely with fi nger-tapping performance in a subset of patients with more unilateral motor impairment. While hypometabolism is limited in the frontal and occipital cortices of PD patients with no cognitive impairment [18] , it becomes more widespread within cortical regions in advanced PD [14] . Further, the relationships of abnormal rCMRglc with clinical symptoms and impaired striatal DAT binding have been examined in de novo untreated PD patients [19] . Correlation analyses showed that the UPDRS motor ratings were negatively correlated with rCMRglc in the premotor cortex (PMC), while putaminal DAT binding was positively correlated with rCMRglc in the premotor, dorsolateral prefrontal, anterior prefrontal, and orbitofrontal cortices. This method also led to a set of disease-related brain templates for PD and atypical PD to aid single-case differential diagnosis [10, 11] . in the inferior/superior parietal and occipital cortices in PD patients with autonomic failure [20] , in agreement with the negative correlation reported between intellectual impairment in PD and rCMRglc in posterior association regions such as the bilateral parietal and occipital gyri [21] .
Both studies provided early indications that cortical hypometabolism may be primarily associated with cognitive dysfunction in PD. It was also found that the relative metabolic activity in typically affected cortical regions was signifi cantly correlated with scores for cognition, but not with those for motor performance and behavior in a combined cohort of PD patients without and with dementia [22] . This measure gave a high sensitivity and specificity of 0.91 and 1.00 for an ultimate clinical diagnosis of dementia.
Indeed, we found that worsening executive dysfunction in non-demented PD patients is related bilaterally with lower rCMRglc in parieto-occipital association regions, and with higher rCMRglc in the cerebellum (Fig. 2) . Extensive ar eas of hypometabolism are also evident in the posterior cortical regions, including the temporo-parieto-occipital, medial parietal, and inferior temporal cortices in PD patients with mild cognitive impairment [18] . These results support the notion that posterior cortical dysfunction is the primary imaging feature of cognitively-impaired PD patients at risk for developing dementia.
Cerebral Blood Flow Studies
Owing to the short half-life of the radiotracer, H 2 O PET has been primarily used in brain activation studies to examine physiological processes underlying motor execution and learning [23, 24] . Nevertheless, this method has also been used to map rCBF alterations in PD patients at rest. Both rCBF and rCMRglc data measured with PET yield similar patterns of subcortical hyperactivity and cortical hypoactivity in PD patients; these are highly comparable to those from resting-state rCBF studies using SPECT perfusion data. For example, one study compared parametric maps of globally normalized rCBF in PD patients and age-matched normal volunteers using SPECT with 99mTc-ethyl cysteinate dimer (ECD) [25] . In patients with early-stage PD, rCBF increased in the bilateral putamen and the right hippocampus relative to controls. In patients with late-stage PD, rCBF increased in the bilateral putamen, pallidum, hippocampus, and cerebellum, the left ventrolateral thalamus, and the right insula and inferior temporal cortex. Thus, signifi cant rCBF changes in PD are associated with the pathophysiology and progression in the functional architecture of thalamocorticobasal ganglia circuits and related pathways.
By contrast, rCBF declines in the supplementary motor area (SMA) and the dorsolateral prefrontal cortex (DLPFC) in PD patients using SPECT with 99mTc-hexamethyl propylene amine oxime (HMPAO) [26] . In a subgroup of patients with
Hoehn-Yahr III/IV, rCBF decreased in the SMA, and in the DLPFC and insular cortex. The degree of rCBF decline in the DLPFC or the insular cortex was correlated with UPDRS motor scores. rCBF was also significantly reduced in the bilateral posterior parietal and occipital cortices in nondemented PD patients relative to normal individuals using SPECT with N-isopropyl-p-[ 123 I]iodoamphetamine (IMP) [27] .
There was a strong positive correlation between the scores in a visual-processing task and rCBF in the right visual association area in PD patients. This work demonstrates that posterior parietal and occipital hypoperfusion is a consistent feature in non-demented PD patients and the latter is likely to underlie impaired visual cognition.
SPECT perfusion data have proven useful for characterizing the unique features of cortical hypoperfusion in PD with dementia. Previous studies in patients with
Hoehn-Yahr III-IV PD showed signifi cant rCBF decreases in the left frontal/parietal association cortices with IMP [28] and in the precuneus and inferior parietal regions with HMPAO [29] , consistent with the impaired visuospatial perception in demented PD. Furthermore, temporal and more extensive parietal hypoperfusion are often seen in demented patients [30] . The cortical hypoperfusion might be clinically useful in discriminating PD patients with dementia from those without cognitive impairment.
In summary, imaging studies of brain metabolism and perfusion have revealed unique and comparable pathological features underlying varying degrees of motor and cognitive dysfunction in patients with PD. The characteristic patterns of abnormal regional cerebral metabolism and perfusion are to a large degree independent of global measures of brain activity in nondemented patients with PD as described previously [3, 31] . The generally similar fi ndings from these two imaging measures of brain function indicate close coupling between cerebral blood fl ow and metabolism in PD under resting conditions.
These results have established molecular-functional-clinical correlates of the impaired cortico-subcortical circuitry in PD.
Functional Brain Imaging: Multivariate Analyses
The measurements of local metabolic rates or blood flow resting state [32] [33] [34] [35] and under brain activation conditions [36] [37] [38] .
The resultant topographic patterns describe functional connectivity and are commonly referred to as diseasespecifi c brain networks.
Metabolic Network Analyses
We have developed a statistical modeling approach to detect and quantify regional functional interactions in neurodegenerative disorders [31, 39] . This method, known originally as the scaled subprofi le model (SSM), uses PCA to identify regional covariance patterns using images from a combined group of patients and controls or a single group of individuals (software freely available at our website http:// www.feinsteinneuroscience.org). These patterns refl ect the covariation of increased or decreased activity in regional brain function in patients relative to the normal population or in relation to the correlation with a behavioral variable.
SSMPCA allows for the prospective quantification of covariance pattern expression in individual subjects.
Subject scores computed from functional brain images can be correlated with clinical or physiological parameters on a single-case basis [3] . Of note, these scores have higher signal-to-noise ratios than decreasing levels of dopaminergic markers such as FDOPA or FPCIT with increasing disease severity. Thus, SSMPCA may offer greater sensitivity for detecting spatiotemporal changes in brain network activity during progression or following therapy.
Many imaging studies have been performed to implement and validate network methods for the diagnosis and evaluation of patients with PD and related movement disorders [39, 40] . Using SSMPCA analysis of FDG PET data we consistently revealed a pattern of regional metabolic covariation characterized by lentiform, thalamic, cerebellar, pontine, and sensorimotor hypermetabolism, along with hypometabolism in the lateral PMC, SMA, and parietooccipital regions (Fig. 3) . The subject scores for this PD-related covariance pattern (PDRP) are elevated in PD patients, and are correlated positively with clinical disease ratings and negatively with striatal FDOPA uptake or DAT binding [3, 41, 42] . This pattern has been confi rmed in multiple cohorts of PD patients [43] [44] [45] and parkinsonian primates [46] scanned with different tomographs. In addition, PDRP expression showed an excellent test-retest reproducibility
FDG PET imaging sessions conducted OFF and ON medications in independent groups of PD patients at early and advanced stages [39] . Moreover, disease-specific covariance patterns for multiple system atrophy (MSA), progressive supranuclear palsy and parkinsonian tremor have also been developed for more accurate differential diagnosis of PD from atypical parkinsonism on a singlecase basis [45, [47] [48] [49] .
SSMPCA analysis of FDG PET data can also reveal the specific networks associated with cognitive dysfunction in PD. By using this method in non-demented PD patients, we identified a covariance pattern that is correlated with memory and executive functioning [50] . This PD-related cognitive pattern (PDCP) is characterized by hypermetabolism in the cerebellar vermis and dentate nuclei and hypometabolism in frontal and parietal association areas (Fig. 4) . Similar results have been reported from VOI-based SSMPCA analysis [51] and another multivariate method based on partial least squares [34] .
PDCP activity predicted memory or visuospatial function, Importantly, the topography of the PD-related metabolic covariance pattern identified in these studies is in line with experimental models of parkinsonism [3, 46] .
Specifically, this supports the notion of enhanced pallidothalamic inhibition as the main functional substrate of parkinsonian bradykinesia. The subject scores for PDRP correlate with objective disease severity ratings and with independent measures of nigrostriatal dopamine function.
Furthermore, the PDRP scores and rCMRglc within key hypermetabolic regions obtained from preoperative FDG
PET scans are related to neuronal firing rates in the GPi and STN measured during stereotaxic neurosurgery [52, 53] .
On the contrary, the PDCP scores did not show such relationships despite their correlation with cognitive impairment in patients. This is further evidence that the PDRP is an indirect measure of an abnormal physiological signal resulting from hyperactivity in the basal gangliathalamic-motor cortical loop.
Blood Flow Network Analyses
PD-related brain network patterns based on SSMPCA can be directly identifi ed and prospectively accessed by using rCBF images from PET or SPECT. VOI-based network analysis of ECD SPECT data from PD patients and agematched healthy controls revealed a pattern characterized by relative increases in putaminal, thalamic, and cerebellar perfusion along with decreases in the frontal operculum and in the medial temporal cortex [54] . The subject scores for this PDRP pattern were significantly increased in PD patients relative to healthy control and MSA groups. These features agree very well with those reported in the PDRP derived from FDG PET images. [50] .) The display represents regions that contributed significantly to the network at P ≤0.01 and were demonstrated to be reliable (P <0.05) by bootstrap estimation.
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Notably, the PET-derived PDRP scores computed from ECD SPECT scans more accurately separate PD patients from normal controls and MSA patients [54, 55] . Receiver operating characteristic analysis indicated that the PDRP measures yielded an overall diagnostic accuracy of 0.91, with a sensitivity of 0.97 and specifi city of 0.71 and 0.80 for distinguishing PD from the other two groups. Hence, the disease-related patterns identified with FDG PET can be reliably assessed in SPECT perfusion scans to discriminate between healthy controls and patients with PD and atypical parkinsonism.
The disease-related patterns seen in PDRP derived from FDG PET and ECD SPECT images are also similar to those revealed by another multivariate brain mapping method based on independent component analysis (ICA). A SPECT study compared differences in rCBF between PD patients and age-matched controls with SPM after decomposing the images into disease-related and unrelated components [33] . In the disease-related components, PD patients revealed significantly higher normalized rCBF in the putamen, pallidum, thalamus, brainstem, and cerebellum, and signifi cant hypoperfusion in the parieto-temporo-occipital cortex, DLPFC, insula, and cingulate gyrus. Importantly, motor UPDRS scores in patients correlated negatively with rCBF in the insula and cingulate gyrus. The abnormal regions revealed by both ICA and PCA are consistent with the current model of parkinsonism.
We have validated the PDRP or PDCP network as a reliable measure of parkinsonism or cognitive dysfunction by computing its activity prospectively in H 2 O and FDG PET scans from PD patients and healthy volunteers [56] . PDRP expression was signifi cantly elevated in PD patients, using PET [42] , indicating that the manifestation of motor symptoms precedes cognitive dysfunction in early PD.
The reliability of PDRP/PDCP expression computed in rCBF scans has also been evaluated within subjects using a test-retest design in mild and advanced PD patients [56] .
These patients were scanned twice within one PDRP/PDCP expression can also be assessed prospectively with rCBF data acquired from arterial spin labeling (ASL) perfusion MRI. We have shown that ASL MRI is comparable to FDG PET in quantifying PDRP network activity in individual patients and healthy controls [57] . Indeed, the PDRP scores in PD patients measured concurrently with both rCBF and rCMRglc images were equally elevated from the controls and significantly correlated with each other.
With further technical refinement this imaging modality has been successful in deriving analogous spatial covariance patterns associated with motor and cognitive dysfunction in PD [58] .
In summary, the motor and cognitive symptoms of 
Effects of Dopaminergic Therapy on Brain Function
PET/SPECT has been used to quantify regional functional changes associated with successful drug therapy. We reported that LD infusion signifi cantly decreased rCMRglc in the putamen, thalamus, cerebellum, and primary motor cortex, along with a significant decline in PDRP expression [59] (Fig. 5) . Changes in pallidal metabolism and PDRP activity were negatively correlated with clinical improvement in UPDRS motor ratings. These confirmed that lentiform hypermetabolism or hyperfusion in PD may be in part reversible by LD [60] . The response to dopaminergic therapy in PD patients may be mediated by the modulation of cortico-striato-pallido-thalamocortical pathways.
PET has played a key role in unraveling the metabolic and neurovascular effects of LD therapy for PD. Both and rCMRglc in PD patients before and after intravenous LD infusion [61] . There was a signifi cant dissociation between PET following unilateral DBS at the internal and external parts of the globus pallidus [9, 65] . Interestingly, unilateral
Vim DBS leads to rCBF decreases in the ipsilateral SMC and the contralateral cerebellum, as well as concurrent increases in the ipsilateral ventral thalamus [66] . Changes in tremor acceleration and rCBF are correlated in the ipsilateral cortical regions; changes in tremor frequency and rCBF are correlated in the contralateral cerebellum and pons. These results suggest that DBS delivers symptomatic relief by modulating the activity of cerebello-thalamocortical pathways.
Stimulation at the STN is considered to be more effective than at the GPi in improving PD symptoms by affecting more than one inhibitory output area of the basal ganglia, i.e. both the GPi and the substantia nigra pars reticulata. An FDG PET study showed that rCMRglc decreased in the left rostral cerebellum with STN-DBS, but increased in both lower thalami extending to the midbrain area and remotely in the right frontal, temporal, and parietal cortices [14] . These data demonstrate an activating effect of DBS on its target structures and suggest a central role of the STN in motor, association, limbic, and cerebellar-basal ganglia circuits.
FDG PET has proven to be useful for directly comparing the specific metabolic effects of different interventions. It has been reported that metabolism is reduced in the GPi and caudal midbrain but elevated in the posterior parietal region following STN stimulation and subthalamotomy [16] . While the metabolic decline in the GPi is greater with a lesion, the metabolic increase is greater with stimulation. PDRP expression is similarly reduced with both treatments. Moreover, we reported that both STN stimulation and LD therapy result in significant metabolic reductions in the putamen/pallidum, SMC, and cerebellar vermis, as well as elevations in the precuneus [67] . Reduction in the lentiform metabolism may refl ect deactivation of the inhibitory basal ganglia output nuclei following suppression of the synaptic activity of STN projections. Comparable declines in PDRP activity have also been observed with both interventions (Fig. 5) , and they are correlated with clinical improvement. This is in excellent agreement with the fi ndings reported with FDG PET in subthalamotomy [68] and DBS at the GPi [9] and STN [69] . These results suggest that effective treatments for PD are facilitated by a common mechanism involving the modulation of pathological brain networks.
It is of interest to note that PDCP expression assessed by rCMRglc and rCBF scans in the same patients was not changed by symptomatic therapy with either intravenous LD infusion or STN-DBS [61] . Hence, PDCP assessment did in the thalamus and midbrain, but declines bilaterally in premotor cortex [70] . Of note, significant correlations are present between improved rigidity and decreased rCBF in the SMA, between improved bradykinesia and increased rCBF in the thalamus, and between improved postural reflexes and decreased rCBF in the pedunculopontine nucleus (PPN). Increased rCBF in the thalamus and midbrain agrees with the rCMRglc results from FDG PET [14, 67] . These data indicate that STN stimulation appears to increase the fi ring of STN output neurons, which enhances inhibition of the thalamocortical projections, ultimately decreasing blood fl ow in cortical targets. Furthermore, blood fl ow increases bilaterally in the STN and in the left lentiform during bilateral STN DBS [71] , but declines in the left SMA (BA 6), induced by STN-DBS under task conditions. One study disclosed that rCBF increases significantly in the SMA, cingulate cortex, and DLPFC with STN stimulation during a motor activation task [73] . This suggests that STN DBS plays a role in enhancing non-primary motor cortical areas, especially the DLPFC showing greater activation than in the GPi during effective stimulation. Bilateral STN DBS worsened the performance of a fast-paced cognitive task of random number generation in PD [74] . Cerebral blood It has been proposed that the axial symptoms in PD can be effectively improved by stimulation at the PPN.
Cerebral blood fl ow was measured by H 2 O PET at rest and during a self-paced motor task of the lower limbs in patients with advanced PD who were treated with unilateral PPN-DBS [75] . hypometabolism [76] . It remains to be seen in a large sample 
